NIH R01 · 2025
Despite recent U.S. FDA approval of therapies for patients with acute myeloid leukemia (AML), clinical outcomes for AML patients continue to remain poor. Other than allogeneic stem cell transplant, there are no effective immunotherapies for AML, and this is, in part, due to a lack of known antigens which are unique to AML and not present on vital normal hematopoietic precursors. Hence, there is an urgent and critical need for novel therapies to improve outcomes in AML. To this end, we recently identified unique expression of the RNA helicase U5 snRNP200, on the surface of AML cells but not normal hematopoietic precursors. Anti-U5 snRNP200 therapeutic antibodies, originally isolated from AML…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.